Guardant Health, Inc. (NASDAQ:GH) Receives $40.60 Consensus Price Target from Analysts

Shares of Guardant Health, Inc. (NASDAQ:GH) have earned a consensus rating of “Moderate Buy” from the sixteen ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and fifteen have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $40.60.

A number of analysts recently commented on the stock. The Goldman Sachs Group upped their price objective on shares of Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Craig Hallum increased their target price on Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. UBS Group lifted their price target on shares of Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, August 21st. Citigroup raised their price objective on shares of Guardant Health from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Finally, Sanford C. Bernstein reduced their target price on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th.

Insiders Place Their Bets

In other Guardant Health news, Director Meghan V. Joyce sold 2,896 shares of the company’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now owns 7,648 shares of the company’s stock, valued at $228,675.20. This represents a 27.47 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Guardant Health

A number of large investors have recently bought and sold shares of the business. JNBA Financial Advisors acquired a new position in shares of Guardant Health during the 3rd quarter valued at $26,000. Ashton Thomas Securities LLC bought a new position in shares of Guardant Health in the 3rd quarter worth $34,000. Quarry LP bought a new position in shares of Guardant Health in the 2nd quarter worth $44,000. Canton Hathaway LLC acquired a new stake in Guardant Health in the 2nd quarter valued at $59,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Guardant Health during the 2nd quarter valued at $71,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Stock Performance

NASDAQ:GH opened at $32.65 on Thursday. The stock has a market capitalization of $4.03 billion, a P/E ratio of -7.70 and a beta of 1.11. Guardant Health has a 1 year low of $15.81 and a 1 year high of $37.04. The firm has a 50 day moving average of $24.22 and a 200-day moving average of $26.83. The company has a current ratio of 6.22, a quick ratio of 5.85 and a debt-to-equity ratio of 16.70.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.33). The firm had revenue of $191.48 million for the quarter, compared to analyst estimates of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.73) EPS. As a group, sell-side analysts anticipate that Guardant Health will post -3.38 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.